A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Clinical Lung Cancer
Saiama N WaqarVassiliki A Papadimitrakopoulou

Abstract

Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). Patients with previously treated SCC with c-MET-positive tumors (H score ≥ 150, Ventana SP44 assay) were enrolled into 2 cohorts: Cohort 1 (immune checkpoint inhibitor-naive) and Cohort 2 (immune checkpoint inhibitor refractory). Telisotuzumab vedotin 2.7 mg/kg was administered intravenously every 3 weeks until disease progression or unacceptable toxicity. Response assessments were performed every 6 weeks. The primary endpoint was response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary endpoints included progression-free survival, overall survival, response within cohort, duration of response, and toxicities. Interim analysis was planned after 20 evaluable patients, with ≥ 3 responses needed to continue enrollment. Forty-nine patients (14% of screened patients) were assigned to S1400K, 28 patients enrolled (15 in Cohort 1 and 13 in Cohort 2), and 23 were eligible. S1400K closed on December 21, 2018 owing to lack of efficacy. Two responses (response rate of 9%; 95% confidence interval, 0%-20%) were reported in cohort 1 ...Continue Reading

References

Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M ParkG Vande Woude
Oct 28, 1998·Trends in Cell Biology·C Birchmeier, E Gherardi
Jul 30, 2003·Cancer Metastasis Reviews·Patrick C MaRavi Salgia
Dec 1, 2011·Therapeutic Advances in Medical Oncology·Shawna Leslie Organ, Ming-Sound Tsao
Jan 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rafal DziadziuszkoFred R Hirsch
Jan 25, 2012·Nature Reviews. Cancer·Ermanno GherardiGeorge Vande Woude
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ahad A Sadiq, Ravi Salgia
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelAmy C Peterson
Jul 26, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fred R HirschRoy S Herbst
Dec 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hans-Ulrich SchildhausReinhard Buettner
Feb 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roy S HerbstVassiliki A Papadimitrakopoulou
Apr 23, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Saiama N WaqarJennifer Sehn
Jul 28, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tony Shu Kam MokKeunchil Park
Aug 31, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jieyi WangEdward B Reilly
Oct 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H StricklerKaren Kelly
Jun 23, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Robin GuoMark G Kris

❮ Previous
Next ❯

Citations

Jul 3, 2021·Marine Drugs·Weimin Zuo, Hang Fai Kwok

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.